physician-dispensed skin care channel, the clinically proven aesthetic benefits of our products, and the potential of our systems to enhance or complement many other facial procedures, we believe we
active ingredients to the appropriate layer of skin is improved.Our Current Products and Products in DevelopmentOur leading product line is the Obagi Nu-Derm System (which consists of cleanser, toner, 4% hydroquinone and sunscreen with a sun protection factor,
new indications for our existing products.We are engaged in an active development program using our proprietary Penetrating Therapeutics technology to enhance the efficacy of established FDA-approved prescription and
opportunities where we believe we can improve the effectiveness of existing products through the application of our Penetrating Therapeutics technology to address conditions such as acne, skin
current Obagi Systems as non-invasive adjunctive therapies to improve certain current skin care procedures, resulting in overall better patient outcomes and satisfaction.3•Creating additional clinically proven Obagi Systems that increase the efficacy of commonly prescribed dermatological agents in addressing existing
In addition, the Obagi Nu-Derm System is subject to seasonality which may cause some sales variability between quarters.•We may fail to expand or develop new product lines.
drugs, which may lead to a requirement for NDA submission for the prescription hydroquinone products we sell.4•Our quarterly operating results are variable, which may cause our stock price to decline.
The information contained in, or that can be accessed through, our website is not part of this prospectus.5THE OFFERINGCommon stock offered by Obagi Medical Products800,000 sharesCommon stock offered by the selling stockholders5,500,000 sharesCommon stock to be outstanding after this offering22,601,961 sharesOver-allotment optionThe underwriters have an option for a period of 30 days to purchase up to 945,000 additional shares of common stock from the selling stockholders to cover over-allotments.Use of proceedsTo repay approximately $9.2 million of debt under our variable rate Credit Agreement with Merrill Lynch Capital and for general corporate purposes.
occurred as of or on the dates indicated and do not purport to represent a projection of our future results.As of June 30, 2007ActualPro formaPro formaas adjusted(in thousands)Consolidated balance sheet data:Cash and cash equivalents$2,796$17,727$8,055Working capital17,03331,19322,083Total assets$46,746$61,677$51,434Long-term debt less current portion9,1639,16353Total liabilities and stockholders' equity$46,746$61,677$61,6777RISK FACTORSAn investment in our common stock involves a high degree of risk.
materially and adversely impacted.To date, substantially all of our revenues have resulted from sales of our principal product line, our Obagi Nu-Derm System and related products.
Obagi Nu-Derm System and related products accounted for 72%, 72% and 68% of our net sales for the year ended December 31, 2004, 2005 and 2006, respectively, and 60% for the six
generate sales.The market for aesthetic and therapeutic skin health products is highly competitive and we expect the intensity of competition to increase in the future.
believe our indirect competitors, who generally sell skin care products directly to consumers, consist of large cosmetic companies, including but not limited to, The Estee Lauder
any required regulatory approval, undesirable side effects could prevent us from achieving or maintaining market acceptance of the product or could substantially increase the costs and expenses of
addition, the Obagi Nu-Derm and Obagi-C Rx Systems contain products that include 4% hydroquinone as an active ingredient and are marketed in the United States
to us could materially and adversely affect our business and impair our ability to commercialize our patent-licensed products.Risks related to our capital requirements and financesIf we fail to generate sufficient cash flow from our operations, we will be unable to continue to develop and commercialize new products.We expect capital outlays and operating expenditures to increase over the next several years as we expand our infrastructure, and our commercialization, clinical
could cause our results to differ materially from those expressed in the forward-looking statements.USE OF PROCEEDSOur estimated net proceeds from the sale of common stock in this offering will be approximately $14.2 million, after deducting estimated underwriting
consolidated financial statements and the related notes included elsewhere in this prospectus.Year ended December 31,Six months endedJune 30,2002200320042005200620062007(unaudited)(unaudited)(in thousands, except per share data)Consolidated statements of income data:Net sales$46,316$49,261$56,256$64,941$77,996$35,926$49,113Net income7,92511,32914,0818,9566,1162,5746,862Net income attributable to common shares:(1)Basic$0.43$0.61$0.79$0.50$0.34$0.14$0.31Diluted$0.40$0.57$0.74$0.50$0.34$0.14$0.31As of December 31,As ofJune 30,200220032004200520062007(unaudited)(unaudited)(in thousands, except per share data)Consolidated balance sheet data:Cash and cash equivalents$8,830$8,739$18,234$3,367$11,298$2,796Working capital9,75513,77125,83915,39721,92317,033Total assets$34,397$35,468$48,704$45,947$52,961$46,746Long-term debt less current portion34443063,19523,0529,163Redeemable preferred stock$22,409$22,175$22,511$—$—$—Cash dividends declared and paid$—$—$—$63,088$—$—Per share$—$—$—$3.60$—$—Total stockholders' equity (deficit)$3,143$6,390$20,083$(26,361)$17,918$25,505(1)On
market tretinoin, used for the topical treatment of acne in the United States, and Obagi Blue Peel products, used to aid the physician in the application of skin peeling actives.Future products.We focus our research and new product development activities on improving the efficacy of established
profitability is primarily dependent upon the continued success of our current product offerings.Critical Accounting Policies and Use of EstimatesOur discussion and analysis of our financial condition and results of operations is based upon our financial statements which have been prepared in accordance
increase in the skin care market, the recent launch of two new product lines and the expansion of our sales force.
results of a study we sponsored by Wirthlin Worldwide Company, an additional 40% of non-dispensing surveyed physicians indicated that they are considering dispensing skin care products.57•Continuing to develop and market new indications for Obagi Systems.